A Case of Chronic Conjunctivitis following Rituximab Therapy

Bautista, Marnelli A.; Quan, Walter D. Y.; Wang, Jun
January 2009
Advances in Hematology;2009, Vol. 2009, p1
Academic Journal
Case Study
The activity of the anti-CD20 monoclonal antibody, rituximab in B-cell non-Hodgkin's lymphoma, with relativelyminimal toxicity has been well established. Adverse effects such as low-grade fever, urticaria, bronchospasm, sporadic tachycardia, and hypotension have been described. However, only a single case of rituximab-related, transient conjunctivitis has been documented in literature. We report an occurrence of chronic, bilateral conjunctivitis in an 88-year-old female diagnosed with stage IV, non-Hodgkin's lymphoma (NHL), who was maintained on rituximab for 12 months. In contrast to the previously described case, our patient developed severe conjunctival inflammation approximately three to four weeks following rituximab induction. Resolution of conjunctivitis occurred within two months after cessation of rituximab treatment.


Related Articles

  • Pixantrone-based regimen associated with lower cardiotoxicity in patients with DLBCL.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p30 

    The article discusses a study by professor Raoul Herbretcht and colleagues at the University Hospital of Strasbourg in France, published in "Annals of Oncology," which found that a pixantrone-based regimen substantially reduced cardiotoxicity in patients with diffuse large B-cell lymphoma (DLBL).

  • Adverse Reaction Research.  // Reactions Weekly;8/30/2008, Issue 1217, p3 

    This section offers updates related to adverse drug reaction research. Researchers from Spain found that the most frequently reported postmarketing adverse reactions associated with trastuzumab and rituximab were heart failure and white blood cell (WBC) disorders respectively. A retrospective...

  • Statins inhibit rituximab effect in rheumatoid arthritis.  // Reactions Weekly;12/4/2010, Issue 1330, p4 

    The article discusses a research study on the role of statin use in inhibiting the antirheumatic effects of rituximab in patients with rheumatoid arthritis (RA), published in the October 18, 2010 issue of the journal "Annals of the Rheumatic Diseases."

  • Rituximab.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p266 

    The article presents a case study on the development of hypogammaglobulinaemia in a male child after the administration of rituximab.

  • Rituximab.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p265 

    The article presents a case study on the development of cytomegalovirus meningoencephalitis in a 67-year-old man during treatment with rituximab.

  • Rituximab.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p264 

    The article presents a case study on the development of cytokine release syndrome (CRS) and acute thrombocytopenia in a 78-year-old woman during treatment with rituximab for moderate thrombocytopenia and a transformed diffuse large B-cell lymphoma.

  • Re-treatment strategy challenges maintenance therapy for rituximab use in low-burden FL.  // Hem/Onc Today;12/25/2011, Vol. 12 Issue 24, p58 

    The article discusses the results of a study by Brad S. Kahl of the University of Wisconsin which suggests the challenge posed by re-treatment strategy to maintenance therapy for rituximab use in low-burden follicular lymphoma (FL).

  • FDA approves rituximab for advanced follicular lymphoma.  // Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p3 

    The article reports on the approval of the drug rituximab by the U.S. Food and Drug Administration (FDA) for the treatment for advanced follicular lymphoma.

  • CORAL: Rituximab-containing regimens produced similar outcomes.  // Hem/Onc Today;9/10/2010, Vol. 11 Issue 17, p22 

    The article discusses research on the overall survival, progression-free survival (PFS) and event-free survival of patients with diffuse large B-cell lymphoma who received rituximab regimens, by C. Gisselbrecht and colleagues, published in the 2010 issue of the "Journal of Clinical Oncology."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics